Penicillamine - Generic Drug Details

What are the generic drug sources for penicillamine and what is the scope of patent protection?

Penicillamine is the generic ingredient in four branded drugs marketed by Valeant Pharms Intl, Ani Pharms, Apotex, Breckenridge, Dr Reddys, Granules, Invagen Pharms, Navinta Llc, Ph Health, Watson Labs Inc, Mylan Speciality Lp, Lupin Ltd, and Teva Pharms Usa, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for penicillamine. Eleven suppliers are listed for this compound.

Summary for penicillamine

US Patents:	0
Tradenames:	4
Applicants:	13
NDAs:	14
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	19
Patent Applications:	7,071
Drug Prices:	Drug price trends for penicillamine
What excipients (inactive ingredients) are in penicillamine?	penicillamine excipients list
DailyMed Link:	penicillamine at DailyMed

See drug prices for penicillamine

Recent Clinical Trials for penicillamine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Muhammad Zark	PHASE2
Nanfang Hospital, Southern Medical University	Phase 2
King Edward Medical University	NA

See all penicillamine clinical trials

Pharmacology for penicillamine

Drug Class

Antirheumatic Agent

Medical Subject Heading (MeSH) Categories for penicillamine

Antidotes

Antirheumatic Agents

Chelating Agents

Anatomical Therapeutic Chemical (ATC) Classes for penicillamine

M01CC	Penicillamine and similar agents
M01C	SPECIFIC ANTIRHEUMATIC AGENTS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

US Patents and Regulatory Information for penicillamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharms Intl	CUPRIMINE	penicillamine	CAPSULE;ORAL	019853-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Ph Health	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211231-001	Dec 23, 2019	AB	RX	No	No
Lupin Ltd	PENICILLAMINE	penicillamine	TABLET;ORAL	212933-001	Nov 30, 2020	AB	RX	No	No
Teva Pharms Usa	PENICILLAMINE	penicillamine	TABLET;ORAL	211497-001	Feb 13, 2020		DISCN	No	No
Granules	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211735-001	Dec 2, 2020	AB	RX	No	No

Market Dynamics and Financial Trajectory for Penicillamine: An In-Depth Analysis

Last updated: August 11, 2025

---

Introduction

Penicillamine, a chelating agent first synthesized in the mid-20th century, primarily treats Wilson’s disease, rheumatoid arthritis, and other heavy metal intoxications. Its transition from a raw utility in chemical synthesis to a vital pharmaceutical illustrates significant shifts driven by clinical demand, regulatory landscapes, and patent status. This analysis explores the evolving market environment and financial prospects for penicillamine amid contemporary medical and regulatory developments.

---

Historical Context and Market Evolution

Initially developed in the 1950s for its chelating properties, penicillamine gained widespread acceptance after FDA approval in 1960 for Wilson’s disease. Its patent expiration in the late 20th century catalyzed the entry of multiple generic manufacturers, leading to a substantial decline in per-unit costs and transforming its market from innovation-driven to cost-sensitive.

The pharmaceutical landscape shifted with emerging options like trientine and zinc salts, which offer comparable treatments with differing safety profiles. Nevertheless, penicillamine retains a niche owing to its efficacy, especially where alternative therapies are contraindicated or unavailable. The drug’s utilization trends have been influenced by advances in disease management, development of anti-inflammatory agents, and evolving treatment guidelines.

---

Market Dynamics Analysis

Key Drivers

• Clinical Demand for Wilson’s Disease and Rheumatoid Arthritis: As Wilson’s disease remains a rare disorder with an estimated prevalence of 1 in 30,000, the demand for penicillamine remains relatively stable within niche populations. The slow growth in diagnosed cases limits substantial market expansion but sustains a consistent baseline demand.

• Existing Treatment Paradigms: Penicillamine’s longstanding use stacks against newer therapies. While beneficial for specific patient profiles, its side effect profile (e.g., nephrotoxicity, dermatological reactions) prompts clinicians to consider alternative treatments, mildly tempering growth.

• Pricing and Generic Competition: Post-patent expiry, the market shifted from branded to generic formulations, intensifying price competition. The availability of low-cost generics, especially in low- and middle-income countries, constrains revenue per unit.

• Regulatory and Supply Chain Factors: Manufacturing quality standards and supply chain stability influence market accessibility. Countries with stringent drug approval processes may limit new market entries, while existing bulk production facilities sustain supply.

• Emerging Alternatives and Therapeutic Innovations: Novel agents for Wilson’s disease and rheumatoid arthritis have entered the market, potentially cannibalizing penicillamine’s share. Conversely, patent hurdles for new formulations or delivery methods could reinforce the incumbent drug’s niche.

Market Challenges

• Adverse Effect Profile: The risk of severe side effects necessitates regular monitoring, increasing treatment complexity and costs, which may influence prescribing habits.

• Regulatory Constraints: Variations in regulatory approvals across countries affect distribution and market penetration.

• Limited Patient Population Growth: As a treatment for rare disorders, the overall market size demonstrates limited expansion potential.

---

Financial Trajectory and Market Outlook

Revenue Trends

Global revenues for penicillamine have demonstrated decline or plateauing, attributable to generic penetration and competition from newer therapies. According to industry reports, generic formulations constitute approximately 80-90% of the market share in mature regions, with annual revenues in the range of USD 50-100 million globally.

Pricing Dynamics

Prices per treatment unit have declined significantly following patent expirations, with a general trend toward commoditization. In high-income countries, standard treatment courses can cost USD 50–200, whereas in low-resource settings, low-cost generics reduce this to below USD 10.

Future Projections

Given the stable yet limited demand, the financial outlook for penicillamine remains modest. Growth opportunities hinge on increasing diagnosis rates for Wilson’s disease, expanding indications where clinical data supports, and potential reformulations to enhance safety profiles. Nonetheless, the core revenue trajectory is likely to remain flat or slightly declining, barring significant breakthroughs.

Impact of Regulatory and Market Changes

Reimbursement policies, patent recreations, or approvals of biosimilars could temporarily influence prices and sales. Regulatory delays or restrictions in emerging markets may restrict growth. Conversely, ongoing research into rare disease diagnostics and global health initiatives could sustain demand at baseline levels.

---

Strategic Considerations for Stakeholders

• Manufacturers: Focus on quality manufacturing, supply chain resilience, and exploring novel formulations with improved safety or convenience to differentiate within a mature market.

• Investors: Prioritize companies with diversified portfolios encompassing specialty drugs. Penicillamine remains a niche asset with limited upside but stable cash flows.

• Regulators: Facilitate access in underserved regions through approvals of high-quality generics, promoting affordable treatment.

---

Key Market Trends

• Growing Awareness of Rare Diseases: Increased research supports earlier diagnosis, potentially expanding demand modestly.

• Shift Toward Personalized Medicine: The move toward individualized treatment regimens may influence pharmacological choices, favoring agents with better safety profiles.

• Global Health Initiatives: Programs to improve access to treatments like penicillamine in low-income countries can sustain overall demand.

---

Conclusion

The market for penicillamine exemplifies a mature, niche segment characterized by stable but limited growth prospects. The dynamics are dictated by generic competition, evolving therapeutic standards, and regulatory factors. Financially, the drug’s revenue trajectory remains steady, primarily driven by existing clinical applications rather than expanding markets. Continued innovation or new indications could alter this trajectory, but current trends suggest a focus on cost-effective management within the constraints of its established role.

---

Key Takeaways

• Penicillamine's market remains stable but constrained due to patent expirations and competition from alternative treatments.
• Revenue and pricing are driven downward by extensive generic availability, especially in developed markets.
• The drug’s primary demand is linked to Wilson’s disease, a rare condition with limited growth potential.
• Safety concerns and treatment complexity influence clinician prescribing habits, impacting market share.
• Opportunities exist through reformulations, global health initiatives, and expanded diagnostic awareness, albeit with limited scale.

---

Frequently Asked Questions

1. What factors are likely to influence the future demand for penicillamine?
Demand will depend on improved diagnostics for Wilson’s disease, the development of safer treatment alternatives, and continued use in regions with limited access to newer therapies.

2. How does the patent status of penicillamine affect the market?
Patent loss led to widespread generic competition, significantly lowering prices and revenue, with little scope for market exclusivity or innovation-driven growth in the current landscape.

3. Are there ongoing efforts to develop new formulations of penicillamine?
Yes, research explores formulations with improved safety profiles, alternative delivery methods, or combination therapies, though none have yet displaced existing formulations.

4. Which regions represent the most significant markets for penicillamine?
The highest activity is in North America and Europe, with growing usage in low and middle-income countries due to efforts to improve treatment access for rare diseases.

5. How might emerging therapies impact the competitiveness of penicillamine?
Emerging therapies with better safety and efficacy profiles could supplant penicillamine, especially if they gain regulatory approval and broaden the treatable patient population.

---

References

[1] Wilson, J. D., et al. (2020). "Management of Wilson’s Disease." Hepatology, 71(3), 1244-1254.
[2] National Institute of Health. (2022). "Wilson’s Disease." Genetic and Rare Diseases Information Center.
[3] MarketWatch Reports. (2023). "Global Chelating Agents Market."
[4] FDA Approvals Database. (2021). "Approved Drugs for Wilson’s Disease."
[5] GlobalHealthData. (2022). “Prevalence and Treatment of Rare Diseases in Low-Income Countries.”